SeLux Diagnostics, Inc.

Selux Diagnostics is a Boston-based company developing precision diagnostics for infectious diseases and combating antimicrobial resistance. Its proprietary Next Generation Phenotyping (NGP) System delivers rapid, high-throughput antimicrobial susceptibility testing (AST) and minimum inhibitory concentration (MIC) results for clinical microbiology labs. By closing the gap between infection identification and susceptibility testing, Selux enables personalized treatment decisions that help halt the spread of antibiotic-resistant superbugs and preserve the efficacy of antibiotics. The company has received FDA Breakthrough Device Designation, FDA clearance for its NGP System, and BARDA funding in recognition of its potential to transform infectious disease treatment.